Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Trial ID or NCT#
NCT01268280
Status
NOT RECRUITING
Purpose
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).
Official Title
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Eligibility Criteria
Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Investigator(s)
Yuen So, MD, PhD
Neuromuscular neurologist,
Neurophysiologist
Professor of Neurology and Neurological Sciences (Adult Neurology), Emeritus
Contact us to find out if this trial is right for you.
Contact
Shirely Paulose
650-724-3792
View on ClinicalTrials.gov
